Y-J Kwon1, Y-J Lee2, B-J Park3, K-W Hong4, D-H Jung5. 1. Department of Family Medicine, Yonsei University College of Medicine, Yong-in Severance Hospital, 225 Geumhakno, Cheoin-gu, Yongin-si, 17046 Gyeonggi-do, Republic of Korea; Department of Medicine, Graduate School of Yonsei University College of Medicine, Seoul, Republic of Korea. 2. Department of Family Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. 3. Department of Family Medicine, Yonsei University College of Medicine, Yong-in Severance Hospital, 225 Geumhakno, Cheoin-gu, Yongin-si, 17046 Gyeonggi-do, Republic of Korea. 4. TheragenEtex BioInstitue Co., Ltd., Suwon, Gyunggi, Republic of Korea. 5. Department of Family Medicine, Yonsei University College of Medicine, Yong-in Severance Hospital, 225 Geumhakno, Cheoin-gu, Yongin-si, 17046 Gyeonggi-do, Republic of Korea. Electronic address: balsan2@yuhs.ac.
Abstract
AIM: In this study, the impact of serum bilirubin on new-onset type 2 diabetes mellitus (T2DM) in Korean adults was investigated. METHODS: Data were obtained from the Korean Genome and Epidemiology Study (KoGES), a population-based prospective cohort study. The study enrolled 8650 adults (4015 men and 4635 women), aged 40 to 69 years, who underwent a mean follow-up of 8.4 years. The study population was divided into quartiles (Q) of serum bilirubin levels, with cut-off points at 0.46, 0.61 and 0.82mg/dL for men, and 0.35, 0.47 and 0.61mg/dL for women. T2DM was defined based on the following data: fasting blood glucose≥7.0mmol/L, HbA1c level≥6.5% or 2-h plasma glucose≥11.1mmol/L during a 75-g oral glucose tolerance test. RESULTS: Over the mean 8.4-year follow-up, 786 participants (9.1%) developed T2DM. Compared with Q1, the odds ratios (ORs) and 95% confidence intervals (CIs) for T2DM incidence were 0.52 (0.36-0.74) in men and 0.56 (0.38-0.83) in women aged ≥50 years, respectively, in the highest Q group after adjusting for possible confounding factors. These significant results persisted in those with impaired glucose tolerance and impaired fasting glucose. CONCLUSION: The results of this study reveal a protective role for serum total bilirubin on new-onset T2DM in Korean men and women. In addition, serum total bilirubin had favourable effects on new-onset T2DM in those with impaired glucose tolerance and impaired fasting glucose.
AIM: In this study, the impact of serum bilirubin on new-onset type 2 diabetes mellitus (T2DM) in Korean adults was investigated. METHODS: Data were obtained from the Korean Genome and Epidemiology Study (KoGES), a population-based prospective cohort study. The study enrolled 8650 adults (4015 men and 4635 women), aged 40 to 69 years, who underwent a mean follow-up of 8.4 years. The study population was divided into quartiles (Q) of serum bilirubin levels, with cut-off points at 0.46, 0.61 and 0.82mg/dL for men, and 0.35, 0.47 and 0.61mg/dL for women. T2DM was defined based on the following data: fasting blood glucose≥7.0mmol/L, HbA1c level≥6.5% or 2-h plasma glucose≥11.1mmol/L during a 75-g oral glucose tolerance test. RESULTS: Over the mean 8.4-year follow-up, 786 participants (9.1%) developed T2DM. Compared with Q1, the odds ratios (ORs) and 95% confidence intervals (CIs) for T2DM incidence were 0.52 (0.36-0.74) in men and 0.56 (0.38-0.83) in women aged ≥50 years, respectively, in the highest Q group after adjusting for possible confounding factors. These significant results persisted in those with impaired glucose tolerance and impaired fasting glucose. CONCLUSION: The results of this study reveal a protective role for serum total bilirubin on new-onset T2DM in Korean men and women. In addition, serum total bilirubin had favourable effects on new-onset T2DM in those with impaired glucose tolerance and impaired fasting glucose.
Authors: Zsu-Zsu Chen; Jinxi Liu; Jordan Morningstar; Brandy M Heckman-Stoddard; Christine G Lee; Samuel Dagogo-Jack; Jane F Ferguson; Richard F Hamman; William C Knowler; Kieren J Mather; Leigh Perreault; Jose C Florez; Thomas J Wang; Clary Clish; Marinella Temprosa; Robert E Gerszten Journal: Diabetes Date: 2019-10-03 Impact factor: 9.461